Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Share-based Compensation (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Share-based Compensation data on record, last reported at $1.2 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 70.4% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $4.6 million, up 65.42%, while the annual FY2024 figure was $3.0 million, 39.87% up from the prior year.
  • Share-based Compensation reached $1.2 million in Q3 2025 per CRVS's latest filing, down from $1.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.3 million in Q2 2025 and bottomed at $492000.0 in Q1 2023.
  • Average Share-based Compensation over 4 years is $773200.0, with a median of $689000.0 recorded in 2024.
  • Peak YoY movement for Share-based Compensation: tumbled 33.42% in 2023, then surged 81.57% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $620000.0 in 2022, then decreased by 7.74% to $572000.0 in 2023, then skyrocketed by 42.13% to $813000.0 in 2024, then surged by 53.63% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $1.2 million in Q3 2025, $1.3 million in Q2 2025, and $1.3 million in Q1 2025.